Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 20, 2019June 20, 2019

Aliqopa Granted FDA’s Breakthrough Therapy Status for Previously Treated Marginal Zone Lymphoma

News

Aliqopa (copanlisib) has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL) who have ... Read more

May 23, 2019

IBI301 (Biosimilar of Rituxan) Meets Primary Endpoints in 2 Clinical Trials in China for B-cell Lymphomas

News

IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two ... Read more

May 7, 2019

Recent Immunosuppression, Persistently High HIV Load Predict Lymphoma Risk

News

Recent immunosuppression, which causes a drop in CD4 T-cell levels, and prolonged exposure to high HIV viral load are two independent predictors of non-Hodgkin’s lymphoma among people living with HIV, a ... Read more

May 3, 2019

Forty Seven, Genentech Continue to Test Triple Immunotherapy Combo in DLBCL

News

Forty Seven and Genentech are extending their agreement to include a third clinical trial evaluating a combination of the investigational 5F9 plus Rituxan (rituximab) and Tecentriq (atezolizumab) in patients with diffuse large B-cell lymphoma (DLBCL). The decision builds on prior ... Read more

May 2, 2019

FasT CAR-T Is Faster, More Potent and Affordable Therapy, Gracell Bio Says

News

Gracell Biotechnologies has developed a platform, called FasT CAR-T, that is able to manufacture its CD19-targeting CAR T-cell product in a single day, as opposed to 14 days for conventional ... Read more

April 16, 2019

Japan Designates Valemetostat for Accelerated Development to Treat PTCL

News

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted Sakigake Designation to valemetostat, an investigational treatment for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The designation is ... Read more

April 11, 2019

Phase 1 Trial of CA-4948 Recruiting Non-Hodgkin’s Lymphoma Patients

News

A Phase 1 clinical trial is recruiting relapsed or refractory non-Hodgkin’s lymphoma patients to determine the safest and most effective dose of the oral therapy CA-4948. The trial is now treating patients ... Read more

March 28, 2019

Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas

News

Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination ... Read more

March 13, 2019

Gamida Cell’s Therapy Shows Promise for Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Gamida Cell’s natural killer cell treatment is a promising approach to treat adults with relapsed or refractory non-Hodgkin’s lymphoma or multiple myeloma, according to early data from an ongoing Phase 1 clinical trial. ... Read more

March 12, 2019

Cell Medica Earns $8.7 Million Grant to Accelerate Off-the-shelf CAR-NKT Cell Therapy

News

Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an $8.7 ... Read more